Zhengye Biotechnology Holding Ltd risk profile
66 Stretched several inputs deteriorating together
Measured 1 September 2026 from ZYBT's filed statements. Recomputed nightly.
66 (Stretched), driven by Competitive position at 78, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 78 | Stretched | Volatile | One-year price volatility — 1,064.7% |
| Operating pressure | 71 | Stretched | Easing | Operating-margin drift — -86.0 percentage points |
| Cash conversion | 21 | Normal | Easing | Capital spending against operating cash — 0.08x |
| Leverage and coverage | 49 | Elevated | Worsening | Interest cover — -13.13x |
| Competitive position | 78 | Stretched | Stable | Revenue-growth gap against peers — -110.1 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for Zhengye Biotechnology Holding Ltd